QSA Global, Inc. and Niowave, Inc. Establish Collaboration to Improve Radium Purification, Increasing Radium Availability and Ac-225 Production
QSA Global, Inc. and Niowave, Inc. Establish Collaboration to Improve Radium Purification, Increasing Radium Availability and Ac-225 Production
BURLINGTON, Mass. and LANSING, Mich., Aug. 12, 2024 /PRNewswire/ -- QSA Global, Inc. (QSA) and Niowave, Inc. (Niowave) are pleased to announce a partnership to transfer Niowave's innovative radium-226 (Ra-226) processing technology to QSA and Co-Develop a Scalable Radium Purification Process. This strategic partnership marks a significant advancement in the field of radiopharmaceutical technology, enhancing the supply chain for critical radioisotopes including actinium-225 (Ac-225).
QSA Global, Inc.（QSA）和Niowave，Inc.（Niowave）很高興宣佈合作，將Niowave的創新鐳-226（Ra-226）處理技術轉移至QSA，並共同開發可擴展的鐳純化過程。這種戰略伙伴關係標誌着放射性製藥技術領域的重大進步，增強了關鍵放射性同位素（包括錒-225）的供應鏈。
Since 2017, Niowave has been at the forefront of processing legacy Ra-226 and actively producing Ac-225. Under the terms of the partnership, QSA now has a license to leverage Niowave's state-of-the-art technology to process Ra-226 sources. The partnership has two components consisting of the development of a scalable Ra-226 purification process and the delivery of radium to Niowave to enable increased Ac-225 production. The newly purified Ra-226 will be supplied to Niowave, increasing Ac-225 production capacity to exceed 5-10 Ci per year using their Linear Accelerator Technology.
自2017年以來，Niowave一直處於處理遺留Ra-226並積極生產Ac-225的前沿。在合作條款的規定下，QSA現在擁有使用Niowave先進技術處理Ra-226資源的許可證書。該合作有兩個部分，包括開發可擴展的Ra-226純化過程和向Niowave提供鐳以促使提高Ac-225產量。新純化的Ra-226將供應給Niowave，使用他們的線性加速器技術，增加Ac-225的生產能力，使其產量每年超過5-10 Ci。
QSA and Niowave will co-develop a scaled radium purification process to meet the ever-increasing demand for Ac-225. QSA will commence multi-year supply of purified Ra-226 to Niowave in early 2025 and extend this supply to third parties in 2026. This collaboration is expected to significantly increase the availability of high-purity Ra-226 to the radioisotope ecosystem and improve the probability that Niowave and other Ac-225 manufacturers can meet the growing demand for Ac-225.
QSA和Niowave將共同開發一種可擴展的鐳純化過程，以滿足日益增長的對Ac-225的需求。QSA將於2025年初開始向Niowave提供多年供應的純化Ra-226，並於2026年將此供應延伸至第三方。這種合作預計將顯著提高高純度Ra-226在放射性同位素生態系統中的可用性，並提高Niowave和其他Ac-225製造商滿足不斷增長的對Ac-225的需求的概率。
"We are excited to partner with Niowave and leverage their advanced Ra-226 processing technology," said Jake Bourn, VP/GM at QSA. "This partnership not only expands and accelerates our capabilities for processing Ra-226 but also helps to meet the increasing demand for Ac-225, which is crucial for advancing cancer treatments. Together, we are committed to driving innovation and meeting the growing needs of the healthcare industry."
QSA公司的副總裁兼總經理Jake Bourn表示：「我們很高興與Niowave建立夥伴關係，並利用他們的先進Ra-226處理技術。這種合作不僅擴展和加速了我們的Ra-226處理能力，還有助於滿足不斷增長的Ac-225需求，這對於推進癌症治療至關重要。我們致力於共同推動創新，滿足醫療行業日益增長的需求。」
Niowave's CEO, Mike Zamiara, added, "Our partnership with QSA represents a significant step forward in Niowave's path to maximize Ac-225 capacity. By combining our expertise with QSA's, we can enhance our production capabilities, better support our partners, and ensure a stable supply of Ac-225. We value QSA's deep industry knowledge and look forward to working with them to drive innovation in the radioisotope space."
Niowave的首席執行官Mike Zamiara補充道：「我們與QSA的合作代表了Niowave最大化Ac-225容量的重要一步。通過將我們的專業技術與QSA的技術相結合，我們可以提高生產能力，更好地支持我們的合作伙伴，並確保Ac-225的穩定供應。我們重視QSA在行業方面的深入知識，並期待與他們合作，在放射性同位素領域推動創新。」
This collaboration signifies a commitment from both companies to innovate and improve the radiopharmaceutical supply chain, ultimately benefiting patients and advancing the field of nuclear medicine.
這種合作體現了兩家公司創新和改善放射性製藥供應鏈的承諾，最終使患者受益，並推動核醫學領域的進步。
About QSA Global, Inc.
關於QSA Global, Inc.
QSA Global, Inc. is a leading provider of high-quality radioisotope products and services. With a strong focus on safety, reliability, and innovation, QSA serves a diverse range of industries including healthcare, industrial, and environmental sectors.
QSA Global, Inc.是一家高質量放射性同位素產品和服務供應商。QSA強調安全、可靠和創新，在醫療、工業和環境等各個行業提供服務。
About Niowave, Inc.
關於Niowave, Inc.
Niowave, Inc. is a pioneer in the production of medical isotopes. Utilizing advanced accelerator technology, Niowave produces critical isotopes for cancer treatment and other medical applications dedicated to improving patient outcomes and advancing healthcare.
Niowave, Inc.是醫學同位素生產的先驅。利用先進的加速器技術，Niowave產生了癌症治療和其他醫療應用所需的關鍵同位素，致力於改善患者結局和推進醫療行業。
For media inquiries, please contact:
媒體垂詢，請聯繫：
Mike Zamiara
Chief Executive Officer
Niowave, Inc.
Phone: 517-999-3475
Email: [email protected]
Mike Zamiara
首席執行官
Niowave, Inc.
電話：517-999-3475
電子郵件：[email protected]
Joe Lapinskas, PhD
Director, Innovation & Marketing
QSA Global, Inc.
Phone: 765-532-6892
Email: [email protected]
Joe Lapinskas，博士
創新和市場總監
QSA Global, Inc.
電話：765-532-6892
電子郵件：[email protected]
SOURCE QSA Global, Inc.
來源：QSA Global, Inc。
譯文內容由第三人軟體翻譯。